|
Oxyphencyclimine
drug data and news
Oxyphencyclimine drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
| Generic name |
Oxyphencyclimine
|
| Brand Names/Synonyms |
Antulcus; CHEMBANK1461; Caridan; Cycmin; Daricol; Daricon; Dominil; Enterex; Gastrix; Manir; Naridan; O7755; Oxifencicliminum [Inn-Spanish]; Oximin; Oxiphencycliminum; Oxyphencyclimine; Oxyphencyclimine Hydrochloride; Oxyphencycliminum [Inn-Latin]; Setrol; Spazamin; Syklifen; Ulcociclinina; Vio-Thene; W-T Anticholinergic; Zamanil |
| Indication |
For the treatment of peptic ulcer disease; Relief of smooth muscle spasms in gastrointestinal disorders |
|
Sponsored links
|
|
Description |
Not Available |
| Pharmacology |
Oxyphencyclimine is a synthetic anticholinergic agent which has been shown in experimental and clinical studies to have a pronounced antispasmodic and antisecretory effect on the gastrointestinal tract. Oxyphencyclimine is an antimuscarinic, anticholinergic drug. |
| Mechanism Of Action |
Oxyphencyclimine binds the muscarinic acetylcholine receptor. It may block all three types of muscarinic receptors including M-1 receptors in the CNS and ganglia, M-2 receptors in the heart (vagus) and M-3 receptors at the parasympathetic NEJ system. The muscarinic acetylcholine receptors mediate various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Oxphencyclimine inhibits vagally mediated reflexes by antagonizing the action of acetylcholine. This in turn reduces the secretion of gastric acids in the stomach. |
Oxyphencyclimine News
(When available) |
[an error occurred while processing this directive] |
| Dosage Forms |
Not Available |
| Drug_Category |
Anticholinergic Agents; Antispasmodics; ATC:A03AA01 |
| Absorption |
Not Available |
| Interactions |
Not Available |
| Toxicity |
Not Available |
| Organisms Affected |
Humans and other mammals |
| Chemical IUPAC Name |
(1-methyl-5,6-dihydro-4H-pyrimidin-2-yl)methyl 2-cyclohexyl-2-hydroxy-2-phenyl-acetate |
| Chemical Formula |
C20H28N2O3 |
| Molecular Weight |
344.448 g/mol |
| Smiles String |
CN1CCCN=C1COC(=O)C(C2CCCCC2)(C3=CC=CC=C3)O |
| Melting Point |
Not Available |
| Water Solubility |
12 mg/ml |
| State |
Solid |
| LogP/Hphobicity |
2.989 |
| Isoelectric Point |
Not Available |
| Biotransformation |
Not Available |
| Half Life |
Not Available |
| Protein Binding [%] |
Not Available |
| RxList Link |
Not Available>RXlist |
|
Sponsored links
|
|
| Drug Reference |
Not Available |
| Drug Type |
Approved Drug |
| Accession No |
APRD00399 |
| CAS Registry Number |
125-53-1 |
| KEGG Compound ID |
C07851 |
| PubChem ID |
SID:10053 |
| PharmGKB ID |
Not Available |
| SwissProt ID |
Not Available |
| GenBank ID |
Not Available |
| Drug ID Number [DIN] |
Not Available
|
|
|
